Skip to Main Content

File this under the “Incredible Shrinking Drug Maker.”

On Thursday, Teva Pharmaceutical reported a batch of sobering developments: the company missed earnings estimates, lowered its profit guidance for the year, cut its dividend by 75 percent, and disclosed plans to axe another 1,000 jobs and close 15 manufacturing plants.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.